Phase II Clinical Trial Scheduled to Begin Summer 2010
Lawrence Steinman, M.D. Added to Raptor Advisory Board
Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.
The Weizmann and Niigata patents cover the use of transglutaminase inhibitors, a class of molecules chemically similar to cysteamine, in the potential treatment of Huntington's Disease and other neurological disorders. These patents add to Raptor's portfolio of intellectual property related to its programs utilizing DR Cysteamine, Raptor's proprietary formulation of delayed-release cysteamine bitartrate, licensed exclusively, with worldwide rights, from the University of California, San Diego ("UCSD").
Ted Daley, President of Raptor's Clinical Division, stated, "This exclusive license covering the Weizmann and Niigata patents significantly strengthens and expands our proprietary position as the compounds claimed in these patents are closely related to our lead clinical compound DR Cysteamine. Additionally, this strategic move to enhance our intellectual property position coincides with our planned clinical trial of DR Cysteamine in collaboration with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") for the potential treatment of Huntington's Disease, as well as our future plans to explore potential treatments for multiple indications utilizing cysteamine and DR Cysteamine."
Huntington's Disease is a rare, progressive, and hereditary neurological disease that often leads to death within 15 to 20 years after diagnosis. The disease is thought to affect as many as 20,000 patients in the U.S. There is no currently available drug that targets the defective gene believed to cause Huntington's Disease, which results in the degeneration of certain nerve cells in the brain. The disease is characterized by uncontrollable movements and mood swings or depression, followed by dementia.
Raptor plans to initiate a Phase II clinical trial this summer of DR Cysteamine in patients with Huntington's Disease under a previously announced collaboration agreement with CHU d'Angers of France. The Company is also developing DR Cysteamine as a potential treatment for nephropathic cystinosis ("cystinosis") and non-alcoholic steatohepatitis ("NASH").
Dr. Patrice Rioux, Raptor's Chief Medical Officer stated: "This clinical trial is intended to build on preclinical work published by Drs. Sandrine Humbert and Frederic Saudou from the Curie Institute in France. Their work demonstrated a potential mechanism for cysteamine in an in vivo preclinical Huntington's Disease model that showed increased brain and blood levels of brain-derived neurotrophic factor ("BDNF"), a growth factor known to be deficient in Huntington's Disease patients, through its inhibition of transglutaminase, a key regulating enzyme in BDNF production."
In October 2008, Raptor entered into an agreement with CHU d'Angers to participate in a Phase II clinical study in Huntington Disease patients. The study is sponsored by CHU d'Angers and will be largely funded by a grant from the French government. Raptor will provide the clinical trial materials for the study and has regulatory and commercial rights to the clinical data generated in the study. CHU d'Angers recently received ethics committee approval to begin the clinical trial. The study will be performed in eight clinical sites throughout France in a 96 patient, placebo-controlled, 18-month trial, followed by an open-label trial with all placebo patients rolling onto DR Cysteamine and all non-placebo patients continuing on DR Cysteamine for up to another 18 months. The primary end point of the trial will be based upon the Unified Huntington's Disease Rating Scale ("UHDRS"). Raptor was granted Orphan Drug Designation in the U.S. by the FDA for cysteamine as a potential treatment for Huntington's Disease in May 2008 and is in the process of applying for Orphan Drug Designation with the European Medicines Agency ("EMEA").
Separately, Raptor announced that Dr. Steinman will join the Company's Advisory Board. Dr. Steinman is a leading researcher in neurological disorders including Huntington's Disease and Multiple Sclerosis ("MS"), and currently serves as the George A. Zimmermann Professor of Neurology and Neurological Sciences, Pediatrics and Genetics at Stanford University. He is a member of the Institute of Medicine of the National Academy of Sciences. He was also co-founder of Bay Hill Therapeutics and Neurocrine Biosciences. The addition of Dr. Steinman to the Advisory Board brings world-class expertise in the development of CNS drugs. He has developed two antigen specific therapies, using DNA vaccines, for MS and Type 1 diabetes. He was senior author on the seminal 1992 Nature article that reported the key role of a particular integrin in brain inflammation which led to the development of the drug Tysabri.
Dr. Steinman said, "I'm excited to join the Raptor team and work with them to examine the possible benefits of DR Cysteamine in the treatment of Huntington's Disease. In previous animal studies published in the journal, Nature Medicine, the team that I worked with found that in a Huntington's Disease preclinical model those given cysteamine had fewer tremors and other abnormal movements and reduced weight loss, as compared to the untreated subjects. Additionally, cystamine appeared to work differently than other Huntington's Disease drugs, and it may be capable of adding to the benefits of existing therapies. This could be a powerful option in the treatment of Huntington's Disease."
Researchers develop the first polymer-based therapeutic for Huntington’s disease